top of page
SCR101 — Topical Therapeutic Candidate for Hypertrophic Scar
Active ingredient
Repurposed small-molecule compound with more than 30 years of human use in other indications
Target indication
Lead indication: Hypertrophic scar
Other dermatologic applications are also under evaluation.
Scientific rationale
Published studies of the active compound underlying SCR101 have reported effects on FAK/integrin-related signaling, ERK phosphorylation, VEGF/KDR-associated pathways, and endothelial function.
These findings provide a rationale for evaluating SCR101 in human hypertrophic scar-derived cells/tissue and relevant preclinical models. They do not yet establish efficacy in hypertrophic scar.
Development Status
A stable topical formulation has been developed. Translational studies are planned to evaluate SCR101 in hypertrophic scar-specific experimental systems and relevant preclinical models.
Delivery to skin tissue
Efficient and rapid delivery
Current therapy
No pharmacologic therapy is currently FDA-approved specifically for the treatment of hypertrophic scar.
Patents
Issued patents in the United States and Japan.
Investigational Product Disclaimer
SCR101 is an investigational product candidate and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities for the indication described. Its safety and efficacy for this investigational use have not been established.
bottom of page